Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 3 9Phase 1/2 5Phase 2/3 3Phase EARLY_PHASE1 2Phase 1 2Phase NA 1

Status

Recruiting 3Withdrawn 1Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2

Conditions

Neuroendocrine Tumors 1Neoplasm Metastasis 1Gastroenteropancreatic Neuroendocrine Tumors 1Gallbladder Neoplasms 1Adenoma, Islet Cell 1

Interventions

Cisplatin 22pembrolizumab 17Drug Therapy 16Carboplatin 15Paclitaxel 12Gemcitabine 12Dexamethasone 12Magnetic Resonance Spectroscopy 10Bevacizumab 10venetoclax 8atezolizumab 8Pemetrexed 8Oxaliplatin 8Docetaxel 8Specimen Handling 7Radiotherapy 7Nivolumab 7Cyclophosphamide 7Capecitabine 7130-nm albumin-bound paclitaxel 7Methotrexate 6durvalumab 5blinatumomab 5Cytarabine 5Androgen Antagonists 5tislelizumab 4spartalizumab 4pertuzumab 4Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Recruiting × Everolimus × Clear all
NCT07165886 2026-04-24

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2/3 Recruiting
298 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

NCT06943755 2026-04-17

STELLAR-311

Exelixis

Phase 2/3 Recruiting
440 enrolled
EndocrineNET

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT05833815 2024-08-13

Addition of Everolimus to Standard of Care in Carcinoma Gallbladder

Banaras Hindu University

Phase 2/3 Recruiting
56 enrolled
Gastrointestinal

Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡